Moderna initiates application for full FDA vaccine approval
Rolling submission would license the jab for individuals 18 and up
Moderna, who plans on revving up its vaccine supply to up to 3 billion doses by next year, has officially begun a biologics license application (BLA) with FDA for approval of its two-dose mRNA shot to prevent Covid-19 in people 18 years of age and older.
The vaccine was granted emergency use authorization (EUA) back in December 2020.
As noted by Stéphane Bancel, Moderna’s CEO, the company will continue to submit Phase III data to support the BLA on a rolling basis over the coming weeks with a request for a priority review. Once the rolling BLA submission is complete, FDA will notify Moderna of when it is formally accepted for review.
Two other manufacturers of the vaccine, Pfizer and BioNTech, initiated the rolling process last month.
Elevate Your Commercial Operations with Close-up CRM
September 6th 2024Discover a powerful, cost-effective, and robust CRM platform that maximizes your budget. Seamlessly integrate data from any source, streamline marketing efforts, and optimize HCP promotion, key account management, and digital marketing campaigns. Reduce CRM costs and reallocate funds to enhance data analytics, market research, and human capital, boosting overall commercial operations impact.
AI-Enabled Pharma CRM Driving Intelligent Customer Engagement
September 6th 2024Discover our unparalleled CRM solution that integrates AI/ML for enhanced stability, security, and performance. Leverage our team of 1000+ experts and 25K+ data provider partners. Our cloud-based SaaS model allows rapid global deployment and scalability, while our clean UX focuses on intuitive AI experience and rapid user adoption. Ensure swift 80% physician onboarding with our intuitive AI platform, speeding strategic integration.
